Pathos AI Inc., a startup using artificial intelligence to develop new oncology drugs, today announced that it has raised $365 million in a late-stage funding.

Pathos AI, the biotech drug developer spun out of Tempus AI, today announced it raised $365 million in Series D financing, which it said brings the company's post-money valuation to about $1.6 ...

The biggest strategic highlight for Tempus AI Inc. (NASDAQ: TEM) during the first quarter was a multi-million dollar deal to build "the world's largest foundation model for oncology." ...

While ethos establishes credibility and logos appeals to logic, pathos taps into the emotional response that often drives decision-making.

“We are excited to collaborate with Tempus and Pathos to advance our data and AI-driven R&D strategy through the development of a multimodal oncology foundation model that we believe will ...

What Socrates can teach us In Q&A, UChicago philosopher Agnes Callard talks new book and cultivating an ‘inherently inquisitive’ approach to conversations with others ...